YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Merck (NYSE:MRK) reported FDA approval of WELIREG plus LENVIMA for adults with advanced renal cell carcinoma after prior PD-1/PD-L1 therapy. The approved combination involves WELIREG at 120 mg taken once daily together with once daily LENV…
Halozyme Therapeutics HALO announced that a Dutch patent court has issued a ruling in its favor in a patent dispute with Merck MRK over Keytruda's subcutaneous (SC) formulation. The court found that Merck's Keytruda SC infringes one of Hal…
Pfizer PFE is a major global player in oncology, with a diversified presence across breast, genitourinary, thoracic, gastrointestinal and hematologic cancers. Its established portfolio of marketed cancer treatments is complemented by a rob…
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to fin…
Moderna MRNA shares are set to join the Nasdaq-100 Index on Oct. 9, marking another milestone for the biotech after its sharp gains this year. The company will replace Warner Bros. Discovery in the index before the opening bell on Friday.…
Eli Lilly LLY is expected to deliver another quarter of robust growth from its oncology portfolio when it reports third-quarter results on Oct. 29. The franchise generated $4.84 billion in revenues in the first half of 2026, up 11% year ov…
Company Logo Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective. Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE)…
Company Logo 135-Page Report Tracks Bayer and Merck's ADEMPAS (Riociguat) as the Leading Therapy as Combination Regimens and Balloon Pulmonary Angioplasty Reshape CTEPH Treatment Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Chronic Pulmonary…
Halozyme's argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock's par…
In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries following a patent dispute. This setback affe…
Tempus, a medical testing and healthcare tech company, has partnered with industry giants like Merck and Moderna to revolutionize healthcare. Founder and chief executive Eric Lefkofsky discusses these partnerships, Tempus's financial strat…
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 1.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Bristol Myers BMY is banking on key drugs like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag to drive top-line growth amid a significant decline in legacy drug sales. These key drugs are part of the company's growth portfolio, w…
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets. Continue Reading
Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets. Before you buy NVIDIA: our AI model's stock p…
[Banknotes with the word DIVIDEND on a blue background. Business concept.] Mohd Azrin Wall Street remains close to record territory, even as a steady rise in Treasury yields gives some investors reason for caution. The S&P 500 (SP500 [http…
Collaboration to Support Potential Commercialization of Intismeran Autogene CHICAGO, October 07, 2026--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization o…
In the latest trading session, Merck (MRK) closed at $141.94, marking a +1.72% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tec…
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses. Continue Reading
BTIG on Tuesday downgraded Personalis (PSNL [https://seekingalpha.com/symbol/PSNL]) to Neutral from Buy, noting that Tempus AI (TEM [https://seekingalpha.com/symbol/TEM]), which has agreed to acquire the cancer test maker, will succeed in…
Merck's MRK stock has declined 7.2% in a month. Investors are looking at this correction as a pullback after a strong run rather than a deterioration in its core business. The stock has surged roughly 60% over the past year. It also reache…
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things ab…
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
The Dow Jones index rises Monday. Brazil stocks soar on election results. Microsoft and SpaceX shine on the stock market today. Continue Reading
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says. Continue Reading
The Dow Jones index falls Monday. Brazil stocks soar on Brazil election results. Microsoft and SpaceX shine on the stock market today. Continue Reading
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says. Continue Reading
[Pneumococcal vaccine in a vial, immunization and treatment of infection] Kittisak Kaewchalun /iStock via Getty Images * Vaxcyte (PCVX [https://seekingalpha.com/symbol/PCVX]) is up ~32% in Monday morning trading after reporting phase 3 top…
Shares of Precigen PGEN have witnessed a sharp increase in the past three months, driven by growing investor optimism surrounding the strong commercial performance of the company's sole marketed drug, Papzimeos (zopapogene imadenovec-drba)…
Stock Market Today: The Dow Jones index falls Monday as Treasury yields climb. Nvidia stock rallies above a new buy point. Continue Reading
Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck. Continue Reading
Vaxcyte Inc.(NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine. The trial assessed the safety, tolerabil…
Stock Market Today: The Dow Jones index wavers Monday as Treasury yields rise. Nvidia stock hits a new buy point. Continue Reading
FutureBrand Hispanic America onboards Vicapsys and delivers a unified visual identity for Vicapsys Life Sciences and its Stateline subsidiary Two linked brands under one visual system: Vicapsys as the umbrella brand and Stateline as the op…
Company Logo Dublin, Oct. 05, 2026 (GLOBE NEWSWIRE) -- "Custom Recombinant Proteins Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global custom recombinant proteins market was valued at…